View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
December 21, 2014

Brainlab’s multiple metastases planning software secures FDA clearance

Software-driven medical technology developer Brainlab has secured 510(k) clearance from US Food and Drug Administration (FDA) for two software modules for radiation oncologists and neurosurgeons.

Software-driven medical technology developer Brainlab has secured 510(k) clearance from US Food and Drug Administration (FDA) for two software modules for radiation oncologists and neurosurgeons.

The company’s Adaptive Hybrid Surgery and Automatic Brain Metastases Planning software, part of the Brainlab Elements portfolio, builds on the company’s aim to enhance access and consistency of patient care.

Brainlab president Stefan Vilsmeier said: "FDA clearance of these software modules marks a critical milestone in the Brainlab vision of indication-specific tools.

"We expect their capabilities, efficiency and usability to help change the way certain life-threatening diseases are treated."

"A complete set of automated tools will allow adjuvant radiosurgery analysis at any time, while planning and performing a surgical resection."

Adaptive Hybrid Surgery was designed to help physicians balance surgical risk with radiosurgical toxicity for multi-disciplinary treatment of skull-base tumours.

In addition, a complete set of automated tools will allow adjuvant radiosurgery analysis at any time, while planning and performing a surgical resection.

The Elements Intraoperative Structure Update will gather residual tumour volumes, based on points acquired inside the resection cavity, whereas an intuitive traffic light display offers comprehensive information regarding tumour coverage and critical dose constraints for calculated treatment plans.

Designed to consistently and rapidly generate radiosurgery plans for efficient treatment of multiple metastases, Automatic Brain Metastasis Planning software enables clinicians to plan and treat multiple brain metastases with time and dose efficiencies, while helping to minimise exposure to healthy surrounding tissue.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU